Bharat Parenterals Ltd vs Rubicon Research Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Bharat Parenterals Ltd is ₹ 1249 as of 05 May 15:30 . The P/E Ratio of Bharat Parenterals Ltd changed from 9.4 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Rubicon Research Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Bharat Parenterals Ltd changed from ₹ 192 crore on March 2021 to ₹ 680.55 crore on March 2025 . This represents a CAGR of 28.80% over 5 yearsThe Market Cap of Rubicon Research Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Bharat Parenterals Ltd for the Dec '25 is ₹ 66.52 crore as compare to the Sep '25 revenue of ₹ 68.15 crore. This represent the decline of -2.39% The revenue of Rubicon Research Ltd for the Dec '25 is ₹ 479.32 crore as compare to the Sep '25 revenue of ₹ 412.72 crore. This represent the growth of 16.14% The ebitda of Bharat Parenterals Ltd for the Dec '25 is ₹ 3.07 crore as compare to the Sep '25 ebitda of ₹ 4.35 crore. This represent the decline of -29.43% The ebitda of Rubicon Research Ltd for the Dec '25 is ₹ 111.91 crore as compare to the Sep '25 ebitda of ₹ 94.99 crore. This represent the growth of 17.81% The net profit of Bharat Parenterals Ltd changed from ₹ -8.84 crore to ₹ -9.67 crore over 7 quarters. This represents a CAGR of 5.26% The net profit of Rubicon Research Ltd changed from ₹ 25.57 crore to ₹ 72.8 crore over 7 quarters. This represents a CAGR of 81.83% The Dividend Payout of Bharat Parenterals Ltd changed from 1.78 % on March 2023 to 2.6 % on March 2025 . This represents a CAGR of 13.46% over 3 yearsThe Dividend Payout of Rubicon Research Ltd changed from -1.5 % on March 2023 to 0.18 % on March 2025 . This represents a CAGR of NaN% over 3 years .

About Bharat Parenterals Ltd

Bharat Parenterals Limited was incorporated in September, 1992 in Gujarat and promoted by Ramesh Desai and Bharat Desai.
The Company is engaged in the business of manufacturing drugs, pharmaceutical formulations and ayurvedic products at its plant in Baroda.
It has set-up a fully integrated and modern plant as per WHO standards at Haripura near Baroda for manufacturing pharmaceutical formulations, life saving drugs, parenterals and antibiotics. In 2016, Varenyam Healthcare Private Limited was incorporated as wholly owned subsidiary company on 09 July, 2016.
Innoxel Lifesciences was incorporated as wholly owned subsidiary company effective 16th October, 2020.
Varenyam Biolifesciences got incorporated as wholly owned subsidiary company effective from 28th June, 2022.

About Rubicon Research Ltd

Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from Rubicon Consultants Private Limited' to Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002.
The Company's status got converted from a Private Company to a Public Company, the name was changed from Rubicon Research Private Limited' to Rubicon Research Limited'.
A fresh Certificate of Incorporation dated July 23, 2024 was issued by the Central Processing Centre, Manesar, Haryana. Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products.

FAQs for the comparison of Bharat Parenterals Ltd and Rubicon Research Ltd

Which company has a larger market capitalization, Bharat Parenterals Ltd or Rubicon Research Ltd?

Market cap of Bharat Parenterals Ltd is 868 Cr while Market cap of Rubicon Research Ltd is 16,073 Cr

What are the key factors driving the stock performance of Bharat Parenterals Ltd and Rubicon Research Ltd?

The stock performance of Bharat Parenterals Ltd and Rubicon Research Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Parenterals Ltd and Rubicon Research Ltd?

As of May 5, 2026, the Bharat Parenterals Ltd stock price is INR ₹1259.45. On the other hand, Rubicon Research Ltd stock price is INR ₹975.6.

How do dividend payouts of Bharat Parenterals Ltd and Rubicon Research Ltd compare?

To compare the dividend payouts of Bharat Parenterals Ltd and Rubicon Research Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.